OncoMatch/Clinical Trials/NCT01917552
Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05): CATALYSIS
Is NCT01917552 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies capecitabine for gastric cancer.
Treatment: capecitabine — multi-center, prospective, randomized, open-label phase III
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Gastric Cancer
Disease stage
Required: Stage IB
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: chemotherapy
Previous chemotherapy or radiotherapy for the currently treated gastric cancer
Cannot have received: radiation therapy
Previous chemotherapy or radiotherapy for the currently treated gastric cancer
Lab requirements
Blood counts
ANC >1,500/uL, Platelets 100,000/uL, and Hb > 8.0 g/dL
Kidney function
serum creatinine < 1.5 mg/dL
Liver function
bilirubin < 1.5 mg/dL, ALT and AST < 3 times upper limit of normal
Cardiac function
No clinically significant (i.e. active) cardiac disease: e.g. unstable angina, symptomatic coronary artery disease, NYHA grade II or greater congestive heart failure or serious cardiac arrhythmia requiring medication or myocardial infarction within the last 6 months
Adequate bone marrow function (ANC >1,500/uL, Platelets 100,000/uL, and Hb > 8.0 g/dL); Adequate renal function (serum creatinine < 1.5 mg/dL); Adequate hepatic function (bilirubin < 1.5 mg/dL, ALT and AST < 3 times upper limit of normal); Clinically significant (i.e. active) cardiac disease: e.g. unstable angina, symptomatic coronary artery disease, NYHA grade II or greater congestive heart failure or serious cardiac arrhythmia requiring medication or myocardial infarction within the last 6 months [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT01917552 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IB is required.
Is there an age limit?
Yes. Patients must be 74 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages